FilingReader Intelligence

Medicamen Biotech responds to BSE inquiry on price movement

February 25, 2025 at 07:12 PM UTCBy FilingReader AI

Medicamen Biotech (BSE:MEDICAMEQ) has responded to an inquiry from the Bombay Stock Exchange (BSE) regarding a recent surge in its share price. In a communication dated February 25, 2025, the company stated that the price increase is solely attributable to market conditions and that the management is not connected in any way with such increase. The company clarified that there are no undisclosed events or information that would explain the price fluctuation. Medicamen Biotech affirmed its commitment to compliance with SEBI (LODR) Regulations, 2015, and stated that it will continue to make appropriate disclosures in accordance with applicable regulations. The company also stated that it is compliant on the stock price movements. The BSE's inquiry was initiated on February 24, 2025, Ref No.: L/SURV/ONL/PV/AJ/2024-2025/2896. Medicamen Biotech is urging the BSE to take their confirmation on record.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

BSE:MEDICAMEQBombay Stock Exchange

News Alerts

Get instant email alerts when Medicamen Biotech publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →